Paul Vincent Grootendorst : Citation Profile


Are you Paul Vincent Grootendorst?

University of Toronto (10% share)
McMaster University (10% share)

9

H index

6

i10 index

229

Citations

RESEARCH PRODUCTION:

16

Articles

35

Papers

2

Chapters

RESEARCH ACTIVITY:

   29 years (1993 - 2022). See details.
   Cites by year: 7
   Journals where Paul Vincent Grootendorst has often published
   Relations with other researchers
   Recent citing documents: 3.    Total self citations: 12 (4.98 %)

MORE DETAILS IN:
ABOUT THIS REPORT:

   Permalink: http://citec.repec.org/pgr189
   Updated: 2024-04-18    RAS profile: 2024-02-06    
   Missing citations? Add them    Incorrect content? Let us know

Relations with other researchers


Works with:

Authors registered in RePEc who have co-authored more than one work in the last five years with Paul Vincent Grootendorst.

Is cited by:

Jones, Andrew (5)

Crossley, Thomas (5)

Stargardt, Tom (4)

Massard, Nadine (4)

Rice, Nigel (4)

Masiero, Giuliano (4)

Yakovlev, Evgeny (4)

ZHONG, HAI (4)

Baltagi, Badi (4)

Veall, Michael (3)

Hollis, Aidan (3)

Cites to:

DiMasi, Joseph (7)

Saez, Emmanuel (6)

Piketty, Thomas (6)

Philipson, Tomas (5)

Lichtenberg, Frank (4)

Hollis, Aidan (4)

López Casasnovas, Guillem (4)

Newey, Whitney (3)

Danzon, Patricia (3)

Jones, Andrew (3)

Kremer, Michael (3)

Main data


Where Paul Vincent Grootendorst has published?


Journals with more than one article published# docs
Health Policy4
Health Economics3
Journal of Health Economics2

Working Papers Series with more than one paper published# docs
Social and Economic Dimensions of an Aging Population Research Papers / McMaster University12
Centre for Health Economics and Policy Analysis Working Paper Series / Centre for Health Economics and Policy Analysis (CHEPA), McMaster University, Hamilton, Canada8
Quantitative Studies in Economics and Population Research Reports / McMaster University6
Working Papers / Canadian Centre for Health Economics2

Recent works citing Paul Vincent Grootendorst (2024 and 2023)


YearTitle of citing document
2023Therapeutic value of new medicines not submitted to Health Canada 2014-2021: Cross-sectional study. (2023). Lexchin, Joel. In: Health Policy. RePEc:eee:hepoli:v:136:y:2023:i:c:s0168851023001860.

Full description at Econpapers || Download paper

2023Dividend policy issues in the European pharmaceutical industry: new empirical evidence. (2023). Schulenburg, J-Matthias ; Schwarzbach, Christoph ; Basse, Tobias. In: The European Journal of Health Economics. RePEc:spr:eujhec:v:24:y:2023:i:5:d:10.1007_s10198-022-01510-5.

Full description at Econpapers || Download paper

2023The impact of a mandatory universal drug insurance program on health behaviors and outcomes. (2023). Lebihan, Laetitia. In: Health Economics. RePEc:wly:hlthec:v:32:y:2023:i:9:p:2006-2046.

Full description at Econpapers || Download paper

Works by Paul Vincent Grootendorst:


YearTitleTypeCited
2000The Effects of Drug Subsidies on Out-of-Poket Prescription Drug Expenditures by seniors: regional Evidence from Canada. In: CEPR Discussion Papers.
[Full Text][Citation analysis]
paper14
2002The effects of drug subsidies on out-of-pocket prescription drug expenditures by seniors: regional evidence from Canada.(2002) In: Journal of Health Economics.
[Full Text][Citation analysis]
This paper has nother version. Agregated cites: 14
article
2000The Effects of Drug Subsidies on Out-of Pocket Prescription Drug Expenditures by Seniors: Regional Evidence from Canada.(2000) In: Quantitative Studies in Economics and Population Research Reports.
[Full Text][Citation analysis]
This paper has nother version. Agregated cites: 14
paper
2000The Effects of Drug Subsidies on Out-of Pocket Prescription Drug Expenditures by Seniors: Regional Evidence from Canada.(2000) In: Social and Economic Dimensions of an Aging Population Research Papers.
[Full Text][Citation analysis]
This paper has nother version. Agregated cites: 14
paper
2015Intellectual Property Protection And Drug Plan Coverage: Evidence From Ontario In: Working Papers.
[Full Text][Citation analysis]
paper1
2020An Empirical Examination of the Patented Medicine Prices Review Board Price Control Amendments on Drug Launches in Canada In: Working Papers.
[Full Text][Citation analysis]
paper0
2005Distributional effects of `general population prescription drug programs in Canada In: Canadian Journal of Economics.
[Full Text][Citation analysis]
article12
2005Distributional effects of ‘general population’ prescription drug programs in Canada.(2005) In: Canadian Journal of Economics/Revue canadienne d'économique.
[Full Text][Citation analysis]
This paper has nother version. Agregated cites: 12
article
2010New Approaches to Rewarding Pharmaceutical Innovation In: Levine's Bibliography.
[Full Text][Citation analysis]
paper3
2001An Empirical Analysis of Milk Addiction In: Working Papers.
[Citation analysis]
paper54
2004An empirical analysis of milk addiction.(2004) In: Journal of Health Economics.
[Full Text][Citation analysis]
This paper has nother version. Agregated cites: 54
article
2005National Catastrophic Drug Insurance Revisited: Who Would Benefit from Senator Kirbys Recommendations? In: Canadian Public Policy.
[Full Text][Citation analysis]
article0
2003National Catastrophic Drug Insurance Revisited: Who Would Benefit from Senator Kirbys Recommendations?.(2003) In: Quantitative Studies in Economics and Population Research Reports.
[Full Text][Citation analysis]
This paper has nother version. Agregated cites: 0
paper
2003National Catastrophic Drug Insurance Revisited: Who Would Benefit from Senator Kirbys Recommendations?.(2003) In: Social and Economic Dimensions of an Aging Population Research Papers.
[Full Text][Citation analysis]
This paper has nother version. Agregated cites: 0
paper
2011The cost of drug development: A systematic review In: Health Policy.
[Full Text][Citation analysis]
article22
2022The effect of patented drug price on the share of new medicines across OECD countries In: Health Policy.
[Full Text][Citation analysis]
article1
2001On the evaluation of drug benefits policy changes with longitudinal claims data: the policy makers versus the clinicians perspective In: Health Policy.
[Full Text][Citation analysis]
article2
2007The effects of coxib formulary restrictions on analgesic use and cost: Regional evidence from Canada In: Health Policy.
[Full Text][Citation analysis]
article0
2012Prescription Drug Insurance and Reimbursement In: Chapters.
[Full Text][Citation analysis]
chapter1
2006Prescription Drug Insurance and Reimbursement.(2006) In: Chapters.
[Full Text][Citation analysis]
This paper has nother version. Agregated cites: 1
chapter
1993Results of an Investigation into the Integrity of the Ontario Health Survey In: Centre for Health Economics and Policy Analysis Working Paper Series.
[Full Text][Citation analysis]
paper0
1994Does It Matter Whom and How You Ask? Inter and Intra-rater Agreement in the Ontario Health Survey In: Centre for Health Economics and Policy Analysis Working Paper Series.
[Full Text][Citation analysis]
paper9
1995On Becoming 65 in Ontario: Effects of Provincial Drug Plan Eligibility on Utilization of Prescription Medicines In: Centre for Health Economics and Policy Analysis Working Paper Series.
[Full Text][Citation analysis]
paper1
1996Financial Incentives to Dispense Low-Cost Drugs: A Case Study of British Columbia Pharmacare In: Centre for Health Economics and Policy Analysis Working Paper Series.
[Full Text][Citation analysis]
paper2
1998Variance in Pharmacare Coverage Across Canada In: Centre for Health Economics and Policy Analysis Working Paper Series.
[Full Text][Citation analysis]
paper1
1999Health Utilities Index Mark 3: Evidence of Construct Validity for Stroke and Arthritis in a Population Health Survey In: Centre for Health Economics and Policy Analysis Working Paper Series.
[Full Text][Citation analysis]
paper9
1999Beneficiary Cost Sharing Under Canadian Provincial Prescription Drug Benefit Programs: History and Assessment In: Centre for Health Economics and Policy Analysis Working Paper Series.
[Full Text][Citation analysis]
paper6
2001International Experience With Pharmaceutical Policy: Common Challenges and Lessons for Canada In: Centre for Health Economics and Policy Analysis Working Paper Series.
[Full Text][Citation analysis]
paper2
2003Out-of-Pocket Prescription Drug Expenditures and Public Prescription Drug Programs In: IZA Discussion Papers.
[Full Text][Citation analysis]
paper1
2002Out-of-Pocket Prescription Drug Expenditures and Public Prescription Drug Programs.(2002) In: Quantitative Studies in Economics and Population Research Reports.
[Full Text][Citation analysis]
This paper has nother version. Agregated cites: 1
paper
2002Out-of-Pocket Prescription Drug Expenditures and Public Prescription Drug Programs.(2002) In: Social and Economic Dimensions of an Aging Population Research Papers.
[Full Text][Citation analysis]
This paper has nother version. Agregated cites: 1
paper
1999Evidence of Construct Validity for Stoke and Arthritis in a Population Health Survey In: Department of Economics Working Papers.
[Full Text][Citation analysis]
paper2
2002The Impact of Reference Pricing of Cardiovascular Drugs on Health Care Costs and Health Outcomes: Evidence from British Columbia -- Volume I: Summary In: Quantitative Studies in Economics and Population Research Reports.
[Full Text][Citation analysis]
paper1
2002The Impact of Reference Pricing of Cardiovascular Drugs on Health Care Costs and Health Outcomes: Evidence from British Columbia--Volume I: Summary.(2002) In: Social and Economic Dimensions of an Aging Population Research Papers.
[Full Text][Citation analysis]
This paper has nother version. Agregated cites: 1
paper
2002The Impact of Reference Pricing of Cardiovascular Drugs on Health Care Costs and Health Outcomes: Evidence from British Columbia -- Volume II: Technical Report In: Quantitative Studies in Economics and Population Research Reports.
[Full Text][Citation analysis]
paper0
2002The Impact of Reference Pricing of Cardiovascular Drugs on Health Care Costs and Health Outcomes: Evidence from British Columbia--Volume II: Technical Report.(2002) In: Social and Economic Dimensions of an Aging Population Research Papers.
[Full Text][Citation analysis]
This paper has nother version. Agregated cites: 0
paper
2002Do Drug Plans Matter? Effects of Drug Plan Eligibility on Drug Use Among the Elderly, Social Assistance Recipients and the General Population In: Quantitative Studies in Economics and Population Research Reports.
[Full Text][Citation analysis]
paper7
2002Do Drug Plans Matter? Effects of Drug Plan Eligibility on Drug Use Among the Elderly, Social Assistance Recipients and the General Population.(2002) In: Social and Economic Dimensions of an Aging Population Research Papers.
[Full Text][Citation analysis]
This paper has nother version. Agregated cites: 7
paper
2004The Impact of Differential Cost Sharing of Non-Steroidal Anti-Inflammatory Agents on the Use and Costs of Analgesic Drugs In: Social and Economic Dimensions of an Aging Population Research Papers.
[Full Text][Citation analysis]
paper5
2007Effects of Authorized-Generics on Canadian Drug Prices In: Social and Economic Dimensions of an Aging Population Research Papers.
[Full Text][Citation analysis]
paper1
2007A review of instrumental variables estimation in the applied health sciences In: Social and Economic Dimensions of an Aging Population Research Papers.
[Full Text][Citation analysis]
paper6
2007The life expectancy gains from pharmaceutical drugs: a critical appraisal of the literature In: Social and Economic Dimensions of an Aging Population Research Papers.
[Full Text][Citation analysis]
paper2
2009How should we support pharmaceutical innovation? In: Social and Economic Dimensions of an Aging Population Research Papers.
[Full Text][Citation analysis]
paper3
2009Patents, Public-Private Partnerships or Prizes – How should we support pharmaceutical innovation? In: Social and Economic Dimensions of an Aging Population Research Papers.
[Full Text][Citation analysis]
paper0
2011Economic Instruments for Obesity Prevention: Results of a Scoping Review and Modified Delphi Survey In: Monash Economics Working Papers.
[Full Text][Citation analysis]
paper3
2017Differences in Incremental Cost-Effectiveness Ratios for Common Versus Rare Conditions: A Case from Oncology In: PharmacoEconomics - Open.
[Full Text][Citation analysis]
article0
2014Do downturns cause desperation? The effect of economic conditions on suicide rates in Canada In: Applied Economics.
[Full Text][Citation analysis]
article4
2015Newtons First Law as Applied to Pharmacies: Why Entry Order Matters for Generics In: International Journal of the Economics of Business.
[Full Text][Citation analysis]
article2
2005Estimating the price elasticity of expenditure for prescription drugs in the presence of non?linear price schedules: an illustration from Quebec, Canada In: Health Economics.
[Full Text][Citation analysis]
article30
2006A re?examination of the impact of reference pricing on anti?hypertensive drug plan expenditures in British Columbia In: Health Economics.
[Full Text][Citation analysis]
article9
1997Health care policy evaluation using longitudinal insurance claims data: An application of the Panel Tobit estimator In: Health Economics.
[Full Text][Citation analysis]
article12
2017Does rising income inequality affect mortality rates in advanced economies? In: Economics Discussion Papers.
[Full Text][Citation analysis]
paper1
2017Does rising income inequality affect mortality rates in advanced economies?.(2017) In: Economics - The Open-Access, Open-Assessment E-Journal (2007-2020).
[Full Text][Citation analysis]
This paper has nother version. Agregated cites: 1
article

CitEc is a RePEc service, providing citation data for Economics since 2001. Sponsored by INOMICS. Last updated March, 4 2024. Contact: CitEc Team